Mark Veich named chief organizational advancement officer of Parker Institute for Cancer Immunotherapy

The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe

Those of us who have devoted our careers to treating recalcitrant cancers know the heartbreak of walking alongside an individual facing an advanced diagnosis. We not only shoulder the clinical responsibility, but also the emotional weight that accompanies every step of that journey as each patient’s story becomes connected to our own.

June 05, 2026

Vol.52 No.22

By W. Kimryn Rathmell

AI in action: MANAscore tool moves closer to clinic

One of the greatest challenges in cancer immunotherapy is finding the rare immune cells, called tumor-reactive T cells, whose job it is to recognize and eliminate tumor cells.

June 05, 2026

Vol.52 No.22

Cancer Policy

Richard Pazdur joins Friends board

Friends of Cancer Research announced the election of Richard Pazdur to the organization’s board of directors.

June 05, 2026

Vol.52 No.22

By Claire Marie Porter

In Brief

Mina Sedrak and Vijaya Raj Bhatt to co-lead Alliance’s committee on cancer care for older adults

Mina Sedrak, director of the UCLA Center for Cancer and Aging and director of Cancer Control and Survivorship Research at the UCLA Health Jonsson Comprehensive Cancer Center, and Vijaya Raj Bhatt professor and medical director of the Leukemia Program at the University of Nebraska Medical Center, were selected to serve as co-chairs of the Cancer in the Older Adult Committee for The Alliance for Clinical Trials in Oncology.

June 05, 2026

Vol.52 No.22

In Brief

Katrina Armstrong to lead Vagelos Institute for Basic Biomedical Research at Columbia

Katrina Armstrong, Columbia University executive vice president for health and biomedical sciences, Columbia University Irving Medical Center CEO, and dean of the Vagelos College of Physicians and Surgeons, will transition from her current roles to launch the Vagelos Institute for Basic Biomedical Research, a collaboration between Roy and Diana Vagelos and the University.

June 05, 2026

Vol.52 No.22

Cancer Policy

FDA’s acting drug chief, acting vaccines chief, and chief of staff ousted in the wake of Makary departure

In further major FDA shake-ups, three top regulators left the agency on May 15, just days after the resignation of Commissioner Marty Makary.

May 22, 2026

Vol.52 No.20

By Claire Marie Porter

Mark Veich named chief organizational advancement officer of Parker Institute for Cancer Immunotherapy

YOU MAY BE INTERESTED IN

The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe

AI in action: MANAscore tool moves closer to clinic

Richard Pazdur joins Friends board

Mina Sedrak and Vijaya Raj Bhatt to co-lead Alliance’s committee on cancer care for older adults

Katrina Armstrong to lead Vagelos Institute for Basic Biomedical Research at Columbia

FDA’s acting drug chief, acting vaccines chief, and chief of staff ousted in the wake of Makary departure

Renew today!

Subscriber content

Never miss an issue!

Login

Mark Veich named chief organizational advancement officer of Parker Institute for Cancer Immunotherapy

YOU MAY BE INTERESTED IN

The story of daraxonrasib is the ultimate hero’s journeyA narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe

AI in action: MANAscore tool moves closer to clinic

Richard Pazdur joins Friends board

Mina Sedrak and Vijaya Raj Bhatt to co-lead Alliance’s committee on cancer care for older adults

Katrina Armstrong to lead Vagelos Institute for Basic Biomedical Research at Columbia

FDA’s acting drug chief, acting vaccines chief, and chief of staff ousted in the wake of Makary departure

Never miss an issue!

Login

The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe